Phendimetrazine Tartrate Er (phendimetrazine tartrate)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Phendimetrazine tartrate is an amphetamine congener that is used as an anorexigenic agent.
Phendimetrazine is used as an adjunct to caloric restriction in the short-term treatment (a few weeks) of exogenous obesity. The anorexigenic effect of sympathomimetic compounds used in the treatment of obesity is temporary, seldom lasting more than a few weeks and tolerance may occur. To help bring about and maintain loss of weight, the patient must be taught to curtail overeating and to consume a suitable diet.
As with other anorexigenic agents, prolonged administration of phendimetrazine is not indicated.
Generic name: phendimetrazine tartrate
Pronunciation: (FEN-dye-meh-TRA-zeen)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Phendimetrazine Tartrate Er
Indications
The following indications are listed for Phendimetrazine Tartrate Er:
- Weight Loss Management For Obese Patient (body mass index 30 or greater)
- Weight Loss Management For Overweight Patient With Bmi 27 To 29 And Weight-Related Comorbidity
Dosing
The usual adult dosage of phendimetrazine tartrate is 35 mg 2 or 3 times daily, given one hour before meals. Dosage should be adjusted to individual response and tolerance and may range from 17.5 mg twice daily to a maximum of 70 mg 3 times daily. The usual adult dosage of the extended-release capsules is 105 mg once daily in the morning.
Phendimetrazine tartrate is administered orally.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
Insulin requirements in patients with diabetes mellitus may be decreased in association with the use of phendimetrazine and the concomitant dietary regimen and weight loss; therefore, phendimetrazine should be used with caution in patients with diabetes mellitus.
Like amphetamines, phendimetrazine may decrease the hypotensive effect of guanethidine.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Safe use of phendimetrazine during pregnancy has not been established. During pregnancy it is questionable whether potential benefits from anorexigenic agents outweigh potential risks and this condition should probably be considered a contraindication to their use, especially during the first trimester. Phendimetrazine should not be used in women who may become pregnant unless, in the opinion of the physician, the potential benefits outweigh the possible risks.
Safe use of phendimetrazine during lactation has not been established.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.